Disposition of 5000000 shares by Dicicco Wendy F of Akari Therapeutics at 0.0017 subject to Rule 16b-3
| AKTX Stock | USD 0.97 0.01 1.02% |
Slightly above 55% of Akari Therapeutics' investors are presently thinking to get in. The analysis of overall sentiment of trading Akari Therapeutics PLC stock suggests that some investors are interested at this time. Akari Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Akari Therapeutics' earnings reports, geopolitical events, and overall market trends.
Akari |
Filed transaction by Akari Therapeutics PLC Officer: Interim Cfo. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at macroaxis.com
Cash Flow Correlation
Akari Therapeutics' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Akari Therapeutics' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.Click cells to compare fundamentals
Akari Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Akari Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Akari Therapeutics Fundamental Analysis
We analyze Akari Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Akari Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Akari Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Earnings Per Share
Earnings Per Share Comparative Analysis
Akari Therapeutics is currently under evaluation in earnings per share category among its peers. Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Akari Therapeutics PLC Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Akari Therapeutics stock to make a market-neutral strategy. Peer analysis of Akari Therapeutics could also be used in its relative valuation, which is a method of valuing Akari Therapeutics by comparing valuation metrics with similar companies.
Peers
Akari Therapeutics Related Equities
| EPIX | ESSA Pharma | 8.70 | ||||
| LYRA | Lyra Therapeutics | 5.56 | ||||
| SNSE | Sensei Biotherapeutics | 4.17 | ||||
| INBX | Inhibrx | 0.47 | ||||
| NXTC | NextCure | 1.20 | ||||
| ORIC | Oric Pharmaceuticals | 1.20 | ||||
| NUVB | Nuvation Bio | 2.13 | ||||
| GLUE | Monte Rosa | 2.22 | ||||
| ERAS | Erasca | 3.05 | ||||
| DSGN | Design Therapeutics | 3.70 |
Additional Tools for Akari Stock Analysis
When running Akari Therapeutics' price analysis, check to measure Akari Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Akari Therapeutics is operating at the current time. Most of Akari Therapeutics' value examination focuses on studying past and present price action to predict the probability of Akari Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Akari Therapeutics' price. Additionally, you may evaluate how the addition of Akari Therapeutics to your portfolios can decrease your overall portfolio volatility.